Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PT-202
- Development stage
- Preclinical
- Lead developer
- p53-Therapeutics
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
PT-202 is a preclinical-stage small molecule xanthine derivative being developed by p53-Therapeutics for the treatment of cancers harboring mutated p53. As an analog of the p53-pathway restoring compound CB002, PT-202 bypasses defective p53 signaling by inducing the integrated stress response (ISR) and upregulating the transcription factors ATF3 and ATF4. This non-canonical pathway activation leads to the transcriptional upregulation of pro-apoptotic p53 target genes, such as NOXA (PMAIP1) and DR5 (TNFRSF10B), thereby promoting apoptotic cell death and cell cycle arrest at the S-phase checkpoint in tumor cells without affecting normal cells.
Beyond the preview
Go deeper on PT-202.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PT-202.